Judgment of the General Court of 15 May 2024 – Dermavita Company v EUIPO – Allergan Holdings France (JUVÉDERM)

(Case T-181/23) ¹

(EU trade mark – Invalidity proceedings – EU word mark JUVÉDERM – Absolute ground for invalidity – No bad faith – Article 51(1)(b) of Regulation (EC) No 40/94 (now Article 59(1)(b) of Regulation (EU) 2017/1001))

Language of the case: English

Parties

Applicant: Dermavita Company S.a.r.l. (Beirut, Lebanon) (represented by: D. Todorov, lawyer)

Defendant: European Union Intellectual Property Office (represented by: E. Markakis, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Allergan Holdings France (Courbevoie, France) (represented by: T. de Haan and S. Vandezande, lawyers, and by J. Day, Solicitor)

Re:

By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 1 February 2023 (Case R 904/2022-4).

Operative part of the judgment

The Court:

1.    Dismisses the action;

2.    Orders Dermavita Company S.a.r.l. to pay the costs.

____________

¹     OJ C 179, 22.5.2023.